CD27 Informations sur la molécule
Molecule Name
CD27 antigen
Alias de la molécule
CD27,TNFRSF7,S152,T14,Tp55
Drug Development Progress
Nombre de médicaments cliniques4
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 2 Clinical
Alias de la cible
CD27 antigen，Tumor necrosis factor receptor superfamily member 7，CD27L receptor，CD27，CD27 Molecule，T-Cell Activation Antigen CD27，TNFRSF7，T14，T Cell Activation Antigen S152，S152. LPFS2，S152，Tp55，Tumor Necrosis Factor Receptor Superfamily， Member 7
Contexte de la molécule
CD Antigen CD27 is also known as Tumor necrosis factor receptor superfamily member 7 (TNFRSF7), which belongs to TNF-receptor superfamily. CD27 / TNFRSF7 is found in most T-lymphocytes. CD27 / TNFRSF7 is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-κB and MAPK8/JNK. CD27 has been shown to interact with SIVA1, TRAF2 and TRAF3.
CD27 Liste de produits
You Have Viewed 0 Of 0 Results
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Varlilumab | CDX-1127 | Phase 2 Clinical | Celldex Therapeutics | Adenocarcinoma; Astrocytoma; Bile Duct Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Lymphoma; Cholangiocarcinoma; Gallbladder Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hormone-Resistant Prostate Neoplasms; Kidney Diseases; Kidney Neoplasms; Large intestine neoplasm; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Primary Effusion; Lymphoma, T-Cell; Lymphomatoid Granulomatosis; Melanoma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Plasmablastic Lymphoma; Prostatic Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms | Details |
| Boserolimab | MK-5890 | Phase 1 Clinical | BioNovion Holding BV | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Solid tumours; Triple Negative Breast Neoplasms | Details |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Anti-CD27 monoclonal antibody (Aduro Biotech) | BION-1402 | Phase 1 Clinical | Aduro Biotech Inc | Neoplasms | Details |